Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
Ignacio I. Wistuba, MD; Keith M. Kerr, FRCPath
Release Date: September 29, 2023
Expiration Date: September 29, 2023
Activity Overview
Non-small cell lung cancer remains a leading cause of cancer deaths around the world. Optimal management of these tumors requires treatment selection informed by a battery of molecular tests to identify actionable targets. Now, the wide range of approved targets necessitates testing a broad range of different genomic aberrations, requiring careful attention and coordination between care teams and pathology. This online activity is designed to provide expert commentary focused on considerations for molecular testing in patients with NSCLC. A series of video interviews with experts in molecular testing is incorporated throughout the program to provide clinical perspectives on these topics.
Target Audience
This educational program is directed toward oncologists and pathologists. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC are also invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize approaches to biomarker testing in NSCLC, including single-gene and panel mutation testing
- Evaluate current clinical data concerning the role of specific mutation- and biomarker-directed therapies in advanced NSCLC
- Analyze current and emerging approaches to testing in the front-line and later-line management of NSCLC
- Recognize approaches to improve coordination of multidisciplinary care across the oncology care team